Endothelial lipase antibodies for treatment of cardiovascular diseases

A cardiovascular and antibody technology, applied in the direction of antibodies, antibody medical components, anti-enzyme immunoglobulin, etc.

Pending Publication Date: 2022-06-21
MEDIMMUNE LLC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are currently no approved therapies that target EL or adequately reduce CV risk

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Endothelial lipase antibodies for treatment of cardiovascular diseases
  • Endothelial lipase antibodies for treatment of cardiovascular diseases
  • Endothelial lipase antibodies for treatment of cardiovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0235] MEDI5884 was administered to cynomolgus monkeys in a single-dose non-Good Laboratory Practice (GLP) PK / pharmacodynamic (PD) study and 2 repeat-dose GLP toxicology studies. Single doses of MEDI5884 administered subcutaneously (SC) up to 30 mg / kg were well tolerated. There were no unplanned deaths, adverse clinical observations, injection site reactions, or adverse effects on body weight. Following repeated SC dosing (dose every 2 weeks) with 10, 30 or 100 mg / kg / dose of MEDI5884 for 1 or 6 months, all animals survived until scheduled sacrifice. No MEDI5884-related changes were observed in clinical observations, ophthalmic evaluations, body weight, behavior, neurophysiology, respiratory rate, injection site irritation score, heart rate, electrocardiogram (ECG), or blood pressure. Treatment-related findings were limited to pharmacologically mediated minimal to moderate increases in TC, HDL-C, LDL-C, and phospholipids at all dose levels. Microscopically, the presence of mi...

Embodiment 3

[0237] MEDI5884 was evaluated in a Phase 1, first-in-human blinded, placebo-controlled, single-dose escalation (SDE) study to evaluate the safety of subcutaneous (SC) administration of MEDI5884 in healthy subjects not receiving statin therapy Sex, PK and PD. Subjects were randomized in a 3:1 ratio to receive 30, 100, 300, or 600 mg of MEDI5884 or placebo; the initial cohort of each dose level was 6 MEDI5884 and 2 placebo subjects. These cohorts were subsequently replicated with subjects of Japanese ancestry to provide data to support clinical studies in Japan. A total of 64 subjects were enrolled at US sites. The duration of follow-up for each cohort varied from 28 days to 90 days after dosing.

[0238] Subjects received a single injection of MEDI5884 (or placebo) at doses of 30 and 100 mg, 3 SC injections of 300 mg dose (100 mg each) or 6 SC injections of 600 mg dose (100 mg each).

[0239] subjects

[0240] The median (SD) age of enrolled subjects was 35.9(9) years; 93...

Embodiment 6

[0315] A combined pharmacology study was performed to evaluate the effect of inhibition of proprotein convertase subtilisin / kexin type 9 (PCSK9) on lipoprotein metabolism following MEDI5884 treatment. The research program is in Figure 9 described in. To better simulate a hypothetical patient population already treated with LDL-C-lowering drugs, healthy cynomolgus monkeys were first given weekly subcutaneous injections of a PCSK9 neutralizing monoclonal antibody (mAb) (10 mg / kg; n=8) or Vehicle, starting on day 0, continued for four weeks to establish a baseline of low LDL-C. The PCSK9 mAb used was HS9 (comprising the VH and VL sequences of SEQ ID NO: 14 and 15, respectively). The HS9 antibody (in the context of the GLP-1 fusion protein known as MEDI4166) is disclosed in Chodorge et al., Sci. Rep. 8:17545 (2018) and International PCT Publication No. WO2015127273, each of which is incorporated by reference in its entirety and into this article.

[0316] Then on day 28 ( F...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, e.g., a subject having cardiovascular disease.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 63 / 104,410, filed October 22, 2020, U.S. Provisional Application No. 62 / 940,164, filed November 25, 2019, and U.S. Provisional Application No. 62 / 932,257, filed November 7, 2019 interests, each of which is incorporated herein by reference in its entirety. 1. Technical field [0003] The present disclosure relates generally to methods of treating diseases or disorders, such as cardiovascular diseases and disorders, using antibodies and antigen-binding fragments thereof that specifically bind human endothelial lipase (EL). Advantageous dosing regimens are provided. 2. Background technology [0004] Endothelial lipase (EL) is a circulating phospholipase that has been recognized as a member of the triglyceride lipase family. EL possesses both phospholipase and triglyceride lipase activities, and it hydrolyzes high-density lipoprotein (HDL) more efficiently than oth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/395A61K9/08
CPCA61K9/0019C07K2317/24C07K2317/76A61K2039/505C07K16/40A61K2039/545C07K2317/33A61K2039/507C07K2317/90A61P9/10
Inventor J.S.格里姆斯比C-Y.金J.法卢恩J.A.西亚S.K.卡拉塔纳西斯R.T.小乔治J.E.勒雷B.T.哈默Y.黄A.I.罗森鲍姆
Owner MEDIMMUNE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap